Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults
Conditions
Interventions
ADM03820
Placebo
Locations
2
United States
PMG Research of Winston-Salem, LLC
Winston-Salem, North Carolina, United States
ICON Early Phase Services, LLC
San Antonio, Texas, United States
Start Date
December 4, 2020
Primary Completion Date
October 6, 2023
Completion Date
October 6, 2023
Last Updated
March 7, 2025
NCT06631287
NCT06850350
NCT05141058
NCT06679140
NCT06160128
NCT07300839
Lead Sponsor
Alachua Government Services, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions